A Multinational Study Assessing an Oral EGFR Inhibitor, DZD6008 in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN1)
Abroad (travel likely)RecruitingPHASE1
Conditions
Non Small Cell Lung Cancer
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Laura and Isaac Perlmutter Cancer Center at NYU Langone Health, New York, New York, United States
Herbert Irving Comprehensive Cancer Center, New York, New York, United States
Virginia Cancer Specialist (NEXT Oncology-Virginia), Fairfax, Virginia, United States
Blacktown Hospital, Blacktown, New South Wales, Australia
Chris O'Brien Lifehouse, Camperdown, New South Wales, Australia